Status:
SUSPENDED
Aromatase (CYP19) Polymorphism Between AI-responsive and AI-resistant Breast Cancer in Korea
Lead Sponsor:
Samsung Medical Center
Conditions:
Polymorphism
CYP19
Eligibility:
FEMALE
Up to 80 years
Brief Summary
Aromatase(CYP19)inhibitor is one of the major antihormonal drug for breast cancer in postmenopausal women. The variation of CYP19 may affect the effect of aromatase inhibitor. However, the incidence o...
Eligibility Criteria
Inclusion
- hormone receptor positiveBreast cancer patient
- postmenopausal women
- first user of aromatase inhibitor
Exclusion
- premenopausal
- The patient who take the other antihormonal therapy
- osteoporosis patients
Key Trial Info
Start Date :
June 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2015
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT01137136
Start Date
June 1 2010
End Date
December 1 2015
Last Update
April 21 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, Seoul, South Korea, 135-710